Article Details
Retrieved on: 2021-07-27 15:04:03
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Here eganelisib was combined with Roche's Tecentriq, and across 38 evaluable patients yielded progression-free survival of 7.4 months and ORR of ...
Article found on: www.evaluate.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here